Enanta Pharmaceuticals INC Form 4 insider transactions

Enanta Pharmaceuticals' Chief Medical Officer, Scott T. Rottinghaus, was granted 110,000 stock options with an exercise price of $13.66, vesting over four years.

Enanta Pharmaceuticals' Chief Scientific Officer, Or Yat Sun, was granted 110,000 stock options with an exercise price of $13.66.

Enanta Pharmaceuticals Inc. CEO Jay R. Luly was granted 310,000 stock options with a $13.66 exercise price, vesting over four years.

Enanta Pharmaceuticals' Chief Medical Officer, Scott T. Rottinghaus, reported a future forfeiture of 2,217 common shares to cover tax obligations from a restricted stock unit award.

Director Terry Vance acquires 15,700 stock options in Enanta Pharmaceuticals, exercisable over one year starting March 13, 2025.

Director Lesley Russell acquired stock options in Enanta Pharmaceuticals, exercisable over the next year.

Kristine Peterson, a director at Enanta Pharmaceuticals, acquired stock options exercisable for 15,700 shares of common stock on March 13, 2025.

Yujiro S. Hata, a director of Enanta Pharmaceuticals, acquired stock options exercisable for 15,700 shares of common stock on March 13, 2025.

Mark G. Foletta, a director at Enanta Pharmaceuticals, acquired stock options for 15,700 shares on March 13, 2025, according to a Form 4 filing.

Director Bruce L.A. Carter of Enanta Pharmaceuticals acquired stock options exercisable for 15,700 shares of common stock on March 13, 2025.

Brendan Luu, Chief Business Officer of Enanta Pharmaceuticals, reports acquisition of 7,500 shares and disposal of 3,326 shares of common stock on February 12, 2025.

Tara Lynn Kieffer, Chief Product Strategy Officer at Enanta Pharmaceuticals, reports acquisition of 7,500 shares and disposal of 3,326 shares to cover withholding taxes.

Scott T. Rottinghaus, Chief Medical Officer of Enanta Pharmaceuticals, reports acquisition of shares through performance share units and disposition of shares to cover withholding taxes.

Or Yat Sun, Chief Scientific Officer of Enanta Pharmaceuticals, reports acquisition of shares through performance share units and subsequent disposal to cover withholding taxes.

Paul J. Mellett, Chief Financial & Administrative Officer of Enanta Pharmaceuticals, reports acquisition of 7,500 shares and disposal of 3,326 shares of common stock on February 12, 2025.

Jay R. Luly, President and CEO of Enanta Pharmaceuticals, reports the acquisition of 25,500 shares of common stock and disposal of 7,484 shares to cover withholding taxes.

Enanta Pharmaceuticals' CEO, Jay R. Luly, reports purchasing 45,000 shares of common stock at an average price of $5.69.

Enanta Pharmaceuticals' Chief Product Strategy Officer, Tara Lynn Kieffer, sold shares to cover tax obligations related to a restricted stock unit award.

Enanta Pharmaceuticals' Chief Business Officer, Brendan Luu, sold 2,283 shares of common stock to cover tax obligations related to a restricted stock unit award.

Enanta Pharmaceuticals' Chief Medical Officer, Scott T. Rottinghaus, sold 866 shares of common stock to cover tax obligations related to a restricted stock unit award.

A top executive at Enanta Pharmaceuticals sold shares to cover tax obligations related to a restricted stock unit award.

Enanta Pharmaceuticals' Chief Financial and Administrative Officer, Paul J. Mellett, sold 2,591 shares of common stock to cover tax obligations related to a restricted stock unit award.

Enanta Pharmaceuticals CEO, Jay R. Luly, sold shares to cover withholding taxes related to a restricted stock unit award.

Chief Business Officer of Enanta Pharmaceuticals, Brendan Luu, forfeited 753 shares of common stock to cover withholding taxes.

Tara Lynn Kieffer, Chief Product Strategy Officer at Enanta Pharmaceuticals, forfeited 753 shares of common stock to cover withholding taxes related to a restricted stock unit award.

Enanta Pharmaceuticals' Chief Scientific Officer, Or Yat Sun, sold 1,595 shares of common stock to cover withholding taxes related to the settlement of restricted stock units.

Paul J. Mellett, Chief Financial and Administrative Officer of Enanta Pharmaceuticals, forfeited 1,595 shares of common stock to cover withholding taxes.

Enanta Pharmaceuticals CEO Jay R. Luly forfeited 3,829 shares of common stock to cover withholding taxes related to the settlement of restricted stock units.

Enanta Pharmaceuticals' Chief Legal Officer, Matthew Paul Kowalsky, was granted 75,000 stock options on November 27, 2024.

Enanta Pharmaceuticals' Chief Business Officer, Brendan Luu, was granted 75,000 stock options on November 27, 2024.